Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2024-05-02 00:00:00 ET · period of report 2024-04-30 · accession 0002001011-24-000050 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-05-02 | 2024-04-30 | LGND | Aryeh Jason | Dir | M - OptEx | $52.30 | +2,406 | 76.8K | +3% | +$125.8K |
| D | 2024-05-02 | 2024-04-30 | LGND | Aryeh Jason | Dir | M - OptEx | $0.00 | -2,406 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-04-30 | M | A | 2,406 | $52.30 | 76,828 | D | — | — | |
| 2 | Derivative | Non-Qualified Stock Option (right to buy) | 2024-04-30 | M | D | 2,406 | $0.00 | 0 | D | $52.30 · — to 2025-04-24 | 2,406 Common Stock | (F2) This Option was previously reported as a Grant of 2,754 shares, which vested in full on April 24, 2016, at an exercise price of $89.75 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. |